Abstract
The catastrophic anti-phospholipid (Asherson's) syndrome (CAPS) is characterised by the rapid chronological development of fulminant thrombotic complications that predominantly affect small vessels and differs from the anti-phospholipid syndrome in its accelerated systemic involvement leading to multi-organic failure. Malignancy may play a pathogenic role in patients with CAPS, whereas infections are more important as triggering factors in patients without malignancies. CAPS patients with malignancies are generally older than CAPS patients without malignancies; they generally have the worst prognosis of the entire CAPS cohort.
MeSH terms
-
Age Factors
-
Antibodies, Antiphospholipid / blood
-
Antiphospholipid Syndrome / blood
-
Antiphospholipid Syndrome / complications
-
Antiphospholipid Syndrome / diagnosis
-
Antiphospholipid Syndrome / epidemiology*
-
Antiphospholipid Syndrome / therapy
-
Catastrophic Illness
-
Germany
-
Hematologic Neoplasms / blood
-
Hematologic Neoplasms / complications
-
Hematologic Neoplasms / diagnosis
-
Hematologic Neoplasms / epidemiology*
-
Hematologic Neoplasms / therapy
-
Humans
-
Incidence
-
Lupus Erythematosus, Systemic / blood
-
Lupus Erythematosus, Systemic / complications*
-
Plasmapheresis
-
Prevalence
-
Prognosis
-
Registries*
-
Risk Factors
-
Thrombosis / blood
-
Thrombosis / immunology*
-
Treatment Outcome
Substances
-
Antibodies, Antiphospholipid